Cipla stock tanks 8% after USFDA warning over issues at MP unit
Warning letter stresses data integrity issues at company embedded with product complaints and microbial contamination
cgmp norms
November 2023
August 2023
US FDA flags ‘significant violations’ of CGMP norms at Gujarat-based Intas Pharma
The FDA asks the company to "correct any violations promptly", failing which the global agency may withhold approval of new applications or supplements listing
